Online citations, reference lists, and bibliographies.
← Back to Search

Late-onset Myasthenia Gravis: A Changing Scene.

J. Aarli
Published 1999 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
The prevalence of myasthenia gravis (MG) among middle-aged and older patients has increased. Patients with early-onset MG live longer than before, but there is also an increase in late-onset MG (onset of the disease after the age of 50 years in patients with no clinical or paraclinical evidence of a thymoma). Epidemiological data support using the age of 50 years to separate early- and late-onset MG. The main immunological difference between early- and late-onset MG is the presence of antibodies to muscle titin, which are detected in approximately 50% of patients with late-onset MG. Treatment of late-onset MG has to be tailored both to the age of the patient and to the immunological findings of that particular form of MG.
This paper references
10.1016/S0003-4975(10)61951-0
Myasthenia gravis in elderly patients.
Y. Monden (1985)
10.1196/annals.1254.053
The Epidemiology of Myasthenia Gravis
L. H. Phillips (1994)
10.1093/AGEING/25.1.56
Myasthenia gravis and elderly people.
F. Schon (1996)
Myasthenia gravis. An analysis of 295 cases.
Simpson Jf (1966)
10.1016/0168-5597(93)90088-7
Neurophysiological evaluation in myasthenia gravis. A comprehensive study of a complete patient population.
F. Somnier (1993)
10.1093/BRAIN/103.3.579
Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis.
D. Compston (1980)
10.1111/j.1468-1331.1997.tb00335.x
Late onset myasthenia gravis
J. Aarli (1997)
10.1006/CLIN.1997.4412
Epidemiology and estimated population burden of selected autoimmune diseases in the United States.
D. Jacobson (1997)
10.1111/j.1600-0404.1994.tb02680.x
Exacerbation of myasthenia gravis after removal of thymomas
F. Somnier (1994)
10.1001/ARCHNEUR.1997.00550220017007
The aging brain. Limitations in our knowledge and future approaches.
R. Katzman (1997)
10.1111/J.1600-0404.1984.TB00825.X
Epidemiology of myasthenia gravis in Norway
A. Storm-Mathisen (1984)
10.1007/s004150050059
Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients
R. Beekman (1997)
10.1111/j.1600-0404.1966.tb05409.x
CSF DYNAMIC DIAGNOSIS OF SPINAL BLOCK VI: Reliability of combined cisterno‐lumbar electromanometrics
O. Gilland (1966)
10.1136/jnnp.64.1.78
Mortality and survival in myasthenia gravis: a Danish population based study
P. Christensen (1998)
Ageing Europe. Philadelphia, Pa: Open University
A Walker (1997)
Paraneoplastic IgG striational autoantibodies produced by clonal thymic B cells and in serum of patients with myasthenia gravis and thymoma react with titin.
C. L. Williams (1992)
10.1212/WNL.47.5.1233
Epidemiologic evidence for a changing natural history of myasthenia gravis
L. H. Phillips (1996)
10.3109/08916939509001933
Titin antibodies in patients with late onset myasthenia gravis: clinical correlations.
G. Skeie (1995)
Paraneoplastic IgG striational autoantibodies produced by clonal thymic B cells and in serum of patients with myasthenia gravis and thymoma react with titin.
Williams Cl (1992)
10.1016/S0079-6123(08)60899-7
Current treatment of myasthenia gravis.
P. Osterman (1990)
Muscular atrophies and dystrophies.
R. D. Adams (1947)
10.1001/ARCHNEUR.1982.00510140016004
Thymectomy in late-onset myasthenia gravis.
C. Olanow (1982)
Muscular atrophies and dystrophies.
Adams Rd (1947)
10.1111/j.1365-2249.1990.tb05440.x
Patients with myasthenia gravis and thymoma have in their sera IgG autoantibodies against titin
J. Aarli (1990)
10.1001/JAMA.1953.02940310038009
Sex and age in myasthenia gravis as critical factors in incidence and remission.
R. S. Schwab (1953)
10.1001/ARCHNEUR.1991.00530190081019
Epidemiology of myasthenia gravis in Denmark. A longitudinal and comprehensive population survey.
F. Somnier (1991)
10.1212/WNL.43.9.1779
Incidence and prevalence of myasthenia gravis in western Denmark
P. Christensen (1993)
10.1002/9780470720721.CH13
Acetylcholine receptor antibody: clinical and experimental aspects.
J. Newsom‐Davis (1982)
10.1016/0022-510X(83)90095-3
Anti-acetylcholine receptor antibodies in myasthenia gravis: Part 1. Relation to clinical parameters in 250 patients
P. Limburg (1983)
10.1016/S0140-6736(75)92203-5
Myasthenia Gravis
D. Elmqvist (1966)
The thymus and myasthenia gravis.
J. Kuks (1993)
10.1212/WNL.42.10.1888
The epidemiology of myasthenia gravis in central and western Virginia
L. H. Phillips (1992)
10.1212/WNL.40.5.786
The relationship of age to outcome in myasthenia gravis
D. Donaldson (1990)
The Thymus and Myasthenia Gravis. Groningen, the Netherlands, Drukkerij Regenboog
Kuks JBM (1992)
10.1016/0165-6147(83)90421-2
Receptors, antibodies and disease Ciba Foundation symposium 90
J. Foreman (1983)



This paper is referenced by
10.4049/jimmunol.1501339
Autoreactive T Cells from Patients with Myasthenia Gravis Are Characterized by Elevated IL-17, IFN-γ, and GM-CSF and Diminished IL-10 Production
Y. Cao (2016)
10.1212/01.wnl.0000176067.32186.a3
Increasing incidence of late-onset anti–AChR antibody–seropositive myasthenia gravis
F. Somnier (2005)
10.1080/14737175.2017.1241144
Myasthenia gravis: recent advances in immunopathology and therapy
John-Ih Lee (2017)
PRECLINICAL STUDIES OF PIXANTRONE AS IMMUNOSUPPRESSIVE DRUG IN THE ANIMAL MODEL OF MYASTHENIA GRAVIS
Chiara Ruocco (2011)
BIOMARCADORES EN EL DIAGNÓSTICO Y TRATAMIENTO DE LA MIASTENIA
Eugenia Martínez Hernández (2014)
10.1016/j.jneuroim.2008.07.012
Thymoma-associated myasthenia gravis: Outcome, clinical and pathological correlations in 197 patients on a 20-year experience
L. Maggi (2008)
10.1002/mus.25068
Epidemiology of myasthenia gravis in Northern Portugal: Frequency estimates and clinical epidemiological distribution of cases
Ernestina Santos (2016)
10.1001/ARCHNEUR.58.6.869
Titin, thymoma, and myasthenia gravis.
J. Aarli (2001)
10.1159/000080093
Incidence of Myasthenia gravis in the Province of Ferrara
I. Casetta (2004)
10.1007/s00508-015-0796-5
Estimation of incidence, prevalence, and age-at-diagnosis of myasthenia gravis among adults by hospital discharge records
Anett Foldvari (2015)
10.15761/jbn.1000119
Late onset myasthenia gravis: A review and report of 24 cases
Andrea L. Porras-Yaurivilca (2018)
10.1016/S1474-4422(15)00145-3
Myasthenia gravis: subgroup classification and therapeutic strategies
N. E. Gilhus (2015)
10.1111/j.1468-1331.2010.03017.x
Course and prognosis of myasthenia gravis: a systematic review
Z.-F. Mao (2010)
10.1136/jnnp.2008.152637
Increasing incidence of elderly onset patients with myasthenia gravis in a local area of Japan
N. Matsui (2009)
10.1371/journal.pone.0036603
Late Onset Myasthenia Gravis Is Associated with HLA DRB1*15:01 in the Norwegian Population
A. Maniaol (2012)
Late Onset Myasthenia Gravis Masquerading As Stroke
A. Leventoğlu (2009)
T cells and costimulatory factors in myasthenia gravis
M. Kakoulidou (2005)
10.4021/JMC.V4I7.1395
Oculobulbar Myasthenia Gravis in an Octogenarian
O. Ogundipe (2013)
10.1371/journal.pone.0164092
Effect of Gender, Disease Duration and Treatment on Muscle Strength in Myasthenia Gravis
G. Citirak (2016)
10.1007/s00415-012-6478-6
Characteristics of late-onset myasthenia gravis
S. Živković (2012)
10.1212/WNL.57.9.1579
Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence?
C. Buckley (2001)
10.1159/000486037
Increased Proportion of Tc17 and Th17 Cells and Their Significant Reduction after Thymectomy May Be Related to Disease Progression in Myasthenia Gravis
Mina Hosseini (2017)
10.1007/s13760-019-01252-x
Late-onset generalized myasthenia gravis: clinical features, treatment, and outcome
Senay Yildiz Celik (2019)
10.1007/978-0-387-79208-8_9
Emerging Therapies for the Treatment of Autoimmune Myasthenia Gravis
K. Kostelidou (2009)
10.1097/00002281-199911000-00007
Paradoxical progress in scleroderma
J. Seibold (1999)
10.12968/HOSP.2001.62.2.1516
An unusual cause of third nerve palsy.
G. Morris (2001)
10.3389/fneur.2020.00604
A Practical Approach to Managing Patients With Myasthenia Gravis—Opinions and a Review of the Literature
M. Farrugia (2020)
10.1136/jnnp.2007.118950
Neurological care and risk of hospital mortality for patients with myasthenia gravis in England
M. Hill (2007)
10.2169/INTERNALMEDICINE.43.189
Retrospective analyses of clinical features and therapeutic outcomes in thymectomized patients with myasthenia gravis at Shinshu University.
Naoko Dohi-Iijima (2004)
How accurate is spirometry at predicting restrictive pulmonary impairment in children with myasthenia gravis.
T. Zielonka (2006)
10.1159/000479228
Prompt Response to Prednisone Predicts Benign Course in MuSK-MG
O. Gungor-Tuncer (2017)
10.1002/(SICI)1097-4598(200006)23:6<946::AID-MUS16>3.0.CO;2-4
Altered expression of costimulatory molecules in myasthenia gravis
N. Teleshova (2000)
See more
Semantic Scholar Logo Some data provided by SemanticScholar